Members

  First name: Anh
  Last name: TRAN
  Email: anh.tran
._
_.
inserm.fr

Research interest


Pharmacoepidemiology, claims data analysis

Education

Degree

2021-present: PhD Candidate in Epidemiology, University of Paris
2020-2021: Master 2 in Methodology and Statistics in Biomedical Research, Paris Saclay University

Exhaustive list of publications

2024


Passaes C, Desjardins D, Chapel A, Monceaux V, Lemaitre J, Mélard A, Perdomo-Celis F, Planchais C, Gourvès M, Dimant N, David A, Dereuddre-Bosquet N, Barrail-Tran A, Gouget H, Guillaume C, Relouzat F, Lambotte O, Guedj J, Müller-Trutwin M, Mouquet H, Rouzioux C, Avettand-Fenoël V, Le Grand R, Sáez-Cirión A
Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8+ T-cells.
Nature Communications 2024, 15, 178.

2023


Claudet I, Caula C, Gallart JC, Tourniaire G, Lerouge-Bailhache M, Michard-Lenoir AP, Tran A, Maleterre A, Huet F, Dufour D, Billaud N, David A, Di Patrizio M, Granjon M, Benoist G, Laguille C, Guitteny MA, Balençon M, Vrignaud B, Basmaci R, Dampfhoffer M, Dubos F, Chappuy H, Minodier P, Médiamolle N, Bréhin C
A French study of cocaine intoxication/exposure in children (2010-2020).
Clinical Toxicology (Philadelphia, Pa.) 2023, 61, 370-378.

Tran A, Zureik M, Sibiude J, Drouin J, Miranda S, Weill A, Dray-Spira R, Duval X, Tubiana S
Prevalence and associated factors of antibiotic exposure during pregnancy in a large French population-based study during the 2010-19 period.
The Journal of Antimicrobial Chemotherapy 2023, 78, 2535-2543.

Bertrand J, Barrail-Tran A, Fayette L, Savic R, Goujard C, Teicher E, Barau C, Pruvost A, Taburet AM, Mentré F, Verstuyft C
Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records.
Antimicrobial Agents and Chemotherapy 2023, 67, e0233918.

Farrugia MA, Le Corvec M, Renou C, Nousbaum JB, Ouizeman DJ, Sire O, Loréal O, Tariel H, Bernard J, Piche T, Tran A, Ait-Oufella H, Landraud L, Gual P, Anty R, The Cytokine Ascites Group n
Mid-Infrared Spectroscopy as a New Tool for Ruling Out Spontaneous Bacterial Peritonitis: A Proof-of-Concept Study.
Biomedicines 2023, 11, 838.

2022


Labarthe L, Gelé T, Gouget H, Benzemrane MS, Le Calvez P, Legrand N, Lambotte O, Le Grand R, Bourgeois C, Barrail-Tran A
Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice.
The Journal of Antimicrobial Chemotherapy 2022, 77, 1094-1101.

Ngono Ayissi K, Gorwood J, Le Pelletier L, Bourgeois C, Beaupère C, Auclair M, Foresti R, Motterlini R, Atlan M, Barrail-Tran A, Le Grand R, Desjardins D, Fève B, Lambotte O, Capeau J, Béréziat V, Lagathu C
Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes.
Cells 2022, 11, 1841.

Mausoléo A, Olivo A, Desjardins D, Sáez-Cirión A, Barrail-Tran A, Avettand-Fenoel V, Noël N, Lagathu C, Béréziat V, Le Grand R, Lambotte O, Bourgeois C
Prolonged Antiretroviral Treatment Induces Adipose Tissue Remodelling Associated with Mild Inflammation in SIV-Infected Macaques.
Cells 2022, 11, 3104.

Gelé T, Gouget H, Dereuddre-Bosquet N, Furlan V, Le Grand R, Lambotte O, Desjardins D, Barrail-Tran A
Pharmacological Validation of Long-Term Treatment with Antiretroviral Drugs in a Model of SIV-Infected Non-Human Primates.
Pharmaceutics 2022, 14, 2282.

2021


Gelé T, Chéret A, Castro Gordon A, Nkam L, Furlan V, Pallier C, Becker PH, Catalan P, Goujard C, Taburet AM, Gasnault J, Gouget H, Barrail-Tran A
Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment.
The Journal of Antimicrobial Chemotherapy 2021, 76, 3280-3285.

2020


Riglet F, Bertrand J, Barrail-Tran A, Verstuyft C, Michelon H, Benech H, Durrbach A, Furlan V, Barau C
Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study.
Drugs in R&D 2020, 20, 331-342.

Gouget H, Noé G, Barrail-Tran A, Furlan V
UPLC-MS/MS method for the simultaneous quantification of bictegravir and 13 others antiretroviral drugs plus cobicistat and ritonavir boosters in human plasma.
Journal of Pharmaceutical and Biomedical Analysis 2020, 181, 113057.

Atwine D, Baudin E, Gelé T, Muyindike W, Mworozi K, Kyohairwe R, Kananura K, Orikiriza P, Nyehangane D, K T Nanjebe D, Furlan V, Verstuyft C, Barrail-Tran A, Taburet AM, Bonnet M, ANRS 12292 Rifavirenz study group
Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial.
The Journal of Antimicrobial Chemotherapy 2020, 75, 1250-1258.

Gelé T, Gouget H, Furlan V, Becker PH, Taburet AM, Lambotte O, Barrail-Tran A
Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries.
Antimicrobial Agents and Chemotherapy 2020, 64, e00895-20.

2019


Barrail-Tran A, Goldwirt L, Gelé T, Laforest C, Lavenu A, Danjou H, Radenne S, Leroy V, Houssel-Debry P, Duvoux C, Kamar N, De Ledinghen V, Canva V, Conti F, Durand F, D'Alteroche L, Botta-Fridlund D, Moreno C, Cagnot C, Samuel D, Fougerou-Leurent C, Pageaux GP, Duclos-Vallée JC, Taburet AM, Coilly A
Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
European Journal of Clinical Pharmacology 2019, 75, 1555-1563.

Gelé T, Furlan V, Taburet AM, Pallier C, Becker PH, Goujard C, Gasnault J, Barrail-Tran A, Chéret A
Dolutegravir Cerebrospinal Fluid Diffusion in HIV-1-Infected Patients with Central Nervous System Impairment.
Open Forum Infectious Diseases 2019, 6, ofz174.

Boulant T, Jousset AB, Bonnin RA, Barrail-Tran A, Borgel A, Oueslati S, Naas T, Dortet L
A 2.5-years within-patient evolution of a Pseudomonas aeruginosa with in vivo acquisition of ceftolozane-tazobactam and ceftazidime-avibactam resistance upon treatment.
Antimicrobial Agents and Chemotherapy 2019, 63, e01637-19, AAC.01637-19.

Bourgeois C, Gorwood J, Barrail-Tran A, Lagathu C, Capeau J, Desjardins D, Le Grand R, Damouche A, Béréziat V, Lambotte O
Specific Biological Features of Adipose Tissue, and Their Impact on HIV Persistence.
Frontiers in Microbiology 2019, 10, 2837.

2018


Beaudreuil S, Schermann JM, Verstuyft C, Barrail-Tran A, Smirnova M, Durrbach A, Becquemont L
Differential pharmacokinetic interaction of cyclosporine and tacrolimus with colchicine in renal allograft recipients.
Clinical Transplantation 2018, 32, e13405.

2016


de Rougemont A, Kaplon J, Fremy C, Legrand-Guillien MC, Minoui-Tran A, Payan C, Vabret A, Mendes-Martins L, Chouchane M, Maudinas R, Huet F, Dubos F, Hober D, Lazrek M, Bouquignaud C, Decoster A, Alain S, Languepin J, Gillet Y, Lina B, Mekki Y, Morfin-Sherpa F, Guigon A, Guinard J, Foulongne V, Rodiere M, Avettand-Fenoel V, Bonacorsi S, Garbarg-Chenon A, Gendrel D, Lebon P, Lorrot M, Mariani P, Meritet JF, Schnuriger A, Agius G, Beby-Defaux A, Oriot D, Colimon R, Lagathu G, Mory O, Pillet S, Pozzetto B, Stephan JL, Aho S, Pothier P, French National Rotavirus Network
Clinical severity and molecular characteristics of circulating and emerging rotaviruses in young children attending hospital emergency departments in France.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2016, 22, 737.e9-737.e15.

2015


Barrail-Tran A, Vincent C, Furlan V, Rosa I, Rosenthal E, Cheret A, Molina JM, Taburet AM, Piroth L, ANRS HC30 QUADRIH Study Group
Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.
Antimicrobial Agents and Chemotherapy 2015, 59, 7903-7905.

Nahon P, Lescat M, Layese R, Bourcier V, Talmat N, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Trinchet JC, Moreau R, Roudot-Thoraval F, ANRS CO12 CirVir and Microcir Groups
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).
Gut 2015

Cotte L, Barrail-Tran A, Vincent C, Valantin MA, Fournier I, Lacombe K, Chevaliez S, Aboulker JP, Taburet AM, Molina JM, ANRS HC26 study group
Telaprevir enhances ribavirin-induced anaemia through renal function impairment.
Antiviral Therapy 2015, 20, 479-486.

2014


Bhatt NB, Barau C, Amin A, Baudin E, Meggi B, Silva C, Furlan V, Grinsztejn B, Barrail-Tran A, Bonnet M, Taburet AM, ANRS 12146-CARINEMO Study Group
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Antimicrobial Agents and Chemotherapy 2014, 58, 3182-3190.

Lan NTN, Thu NTN, Barrail-Tran A, Duc NH, Lan NN, Laureillard D, Lien TTX, Borand L, Quillet C, Connolly C, Lagarde D, Pym A, Lienhardt C, Dung NH, Taburet AM, Harries AD
Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
PloS One 2014, 9, e84866.

2013


Chauvin B, Drouot S, Barrail-Tran A, Taburet AM
Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.
Clinical Pharmacokinetics 2013, 52, 815-831.

Barau C, Furlan V, Yazdanpanah Y, Fagard C, Molina JM, Taburet AM, Barrail-Tran A
Characterization of binding of raltegravir to plasma proteins.
Antimicrobial Agents and Chemotherapy 2013, 57, 5147-5150.

Parienti JJ, Barrail-Tran A, Duval X, Nembot G, Descamps D, Vigan M, Vrijens B, Panhard X, Taburet AM, Mentre F, Goujard C
Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.
Antimicrob Agents Chemother 2013, 57, 2265-71.

Rekić D, Röshammar D, Bergstrand M, Tarning J, Calcagno A, D'Avolio A, Ormaasen V, Vigan M, Barrail-Tran A, Ashton M, Gisslén M, Äbelö A
External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.
The AAPS journal 2013, 15, 308-315.

2012


Savic RM, Barrail-Tran A, Duval X, Nembot G, Panhard X, Descamps D, Verstuyft C, Vrijens B, Taburet AM, Goujard C, Mentré F, ANRS 134–COPHAR 3 Study Group
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
Clinical Pharmacology and Therapeutics 2012, 92, 575-583.

Barau C, Furlan V, Debray D, Taburet AM, Barrail-Tran A
Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children.
British Journal of Clinical Pharmacology 2012, 74, 515-524.

2011


Barau C, Barrail-Tran A, Hemerziu B, Habes D, Taburet AM, Debray D, Furlan V
Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.
Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2011, 17, 1152-1158.

Barrail-Tran A, Taburet AM, Poirier JM, Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique
[Evidence-based therapeutic drug monitoring of lopinavir].
Therapie 2011, 66, 231-238.

Barrail-Tran A, Taburet AM, Poirier JM, pour le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique
[Not Available].
Therapie 2011, 66, 239-246.

2010


Goldwirt L, Barrail-Tran A, Da Cruz M, Taburet AM, Furlan V
Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2010, 878, 456-460.

Barrail-Tran A, Yazdanpanah Y, Goldwirt L, Chêne G, Colin C, Piketty C, Bollens D, Katlama C, Descamps D, Molina JM, Fagard C, Taburet AM, ANRS 139 study group
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.
AIDS (London, England) 2010, 24, 2581-2583.

Barrail-Tran A, Mentré F, Cosson C, Piketty C, Chazallon C, Gérard L, Girard PM, Taburet AM
Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial.
Antimicrobial Agents and Chemotherapy 2010, 54, 614-619.

2009


Bertrand J, Treluyer JM, Panhard X, Tran A, Auleley S, Rey E, Salmon-Céron D, Duval X, Mentré F, COPHAR2-ANRS 111 Study Group
Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.
European Journal of Clinical Pharmacology 2009, 65, 667-678.

2008


Hirt D, Mentré F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Tréluyer JM, COPHAR2- ANRS Study Group
Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
British Journal of Clinical Pharmacology 2008, 65, 548-557.

2007


Chhun S, Rey E, Tran A, Lortholary O, Pons G, Jullien V
Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2007, 852, 223-228.